pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 13·2 min read
save

STAT+: Gene therapy viruses linked to a boy’s tumor

The case for Makary as the WOAT, Cassidy's seat at risk ahead of midterms, and other biotech news from The Readout

May 13, 2026·read at STAT ↗

STAT PlusNewsletterThe Readout Gene therapy viruses linked to a boy’s tumor The case for Makary as the WOAT, Cassidy’s seat at risk ahead of midterms, and other biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenMay 13, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today?

Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get straight into all the news out of D.C.

today.Advertisement Makary is officially out as FDA commissioner President Trump yesterday confirmed that Marty Makary is resigning from his role leading the FDA. Kyle Diamantas, the top food regulator at the agency, will step in as acting commissioner. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 13, 2026 STAT Plus: Drug meant to make gene therapy safer may also make it less effective Biotech May 13, 2026 STAT Plus: Scientists link boy’s tumor to gene therapy viruses, in rare finding Advertisement Matt's Take May 12, 2026 STAT Plus: Why Marty Makary was the worst FDA commissioner in 25 years Politics May 12, 2026 STAT Plus: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in The Readout May 12, 2026 STAT Plus: Hims’ sales miss as telehealth competition grows Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
413 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGUltragenyx Pharmaceutical Inc.
topics
Gene Therapy (AAV)4Oncology3Rare Disease

related stories

  • 16h agoSanofi cuts 229 Blueprint Medicines employeesBioSpace
  • Aug 4J&J pharma leader to retire; Krystal slumps on gene therapy missBioPharma Dive
  • Jul 27Sarepta names former AbbVie R&D exec Michael Severino as next CEOBioSpace
  • Jul 24Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsFierce Biotech
  • Jul 8Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalBioPharma Dive